pharmaceutical investing Revive Therapeutics Provides Corporate Update on its Pharmaceutical Initiatives
pharmaceutical investing Revive Therapeutics Provides an Update on its Psilocybin-Based Pharmaceutical Program
pharmaceutical investing Revive Therapeutics Announces U.S. FDA Recommendation to Proceed Directly Into A Phase 3 Confirmatory Clinical Trial
pharmaceutical investing Revive Therapeutics Announces Research Partnership Agreement with the University of Wisconsin-Madison
pharmaceutical investing Revive Therapeutics Partners with Complete Phytochemical Solutions to Advance Research Initiatives for Psilocybin-Based Pharmaceutical Products
pharmaceutical investing Revive Therapeutics Announces Closing of Second Tranche of Brokered Private Placement
pharmaceutical investing Revive Therapeutics Engages Novotech as Asia-Pacific CRO for Bucillamine in the Treatment of Infectious Diseases
Revive Therapeutics Explores the use of Bucillamine as a Novel Treatment for Infectious Diseases Including COVID-19
Revive Provides Update on its Clinical Development Plan for Cannabidiol in the Treatment of Autoimmune Hepatitis
New Report from KBR Supports Potential for US$1.75/kg Hydrogen from Syntholene's Geothermal-SOEC Platform
New Report from KBR Supports Potential for US$1.75/kg Hydrogen from Syntholene's Geothermal-SOEC Platform
Homerun Resources Inc. Confirms Optimized +4N Purification Plant Pathway and Advances CAPEX Configurations for the SME High-Purity Silica
Tartisan Nickel Corp. Completes Airborne MobileMTm and Borehole Em Geophysical Surveys at the Kenbridge Nickel-Copper-Cobalt Project, Northwestern Ontario; Interpretation Underway
